173192-07-9

Upstream product

• 1198-84-1 4-hydroxymandelic acid 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 

Downstream Products

• 192573-25-4 5-(4-benzyloxyphenyl)-2,2-dimethyl-1,3-dioxolan-4-one 
• 1034809-42-1 4-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)phenyl trifluoromethanesulfonate 
• 1034809-29-4 (2S)-2-{[(2R)-2-fluoro-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanoyl]amino}propanoic acid 
• 1034809-63-6 2-[2-(4-trifluoromethanesulfonyloxyphenyl)propionylamino]propionic acid methyl ester 
• 1034809-33-0 4-{(1R)-1-fluoro-1-methyl-2-[(methylsulfonyl)amino]-2-oxoethyl}phenyl trifluoromethanesulfonate 
• 1034809-44-3 4-(2,2,4-trimethyl-5-oxo-1,3-dioxolan-4-yl)phenyl trifluoromethanesulfonate 
• 1034809-17-0 4-[(1R)-2-amino-1-fluoro-1-methyl-2-oxoethyl]phenyl trifluoromethanesulfonate 
• 1034809-21-6 4-[1-fluoro-2-(methoxyamino)-1-methyl-2-oxoethyl]phenyl trifluoromethanesulfonate 
• 1034809-46-5 2-[4-(trifluoromethanesulfonyloxy)phenyl]-2-hydroxy propanamide 
• 1034809-15-8 4-(1-amino-2-fluoro-1-oxopropan-2-yl)phenyl trifluoromethanesulfonate 
• 1034809-06-7 (2R)-2-fluoro-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanoic acid 
• 1034809-04-5 (2S)-2-fluoro-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanoic acid 
• 1034809-02-3 (R,S)-2-[4-(trifluoromethanesulfonyloxy)phenyl]-2-fluoro-propanoic acid 
• 192573-29-8 (R)-5-(4-benzyloxyphenyl)-2,2-dimethyl-1,3-dioxolan-4-one 

Relevant academic research and scientific papers

2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to (R,S) 2-aryl-2-fluoropropanoic acids, their single enantiomers (R) and (S), their derivatives amides and acylsulfonamides and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the treatment of damages caused by ischemia and reperfusion.

Resolution of racemic carboxylic acid derivatives by Ti-TADDOLate mediated esterification reactions a general method for the preparation of enantiopure compounds

The Lewis-acid mediated transfer of an alkoxide ligand from the chiral ligand sphere of Ti-TADDOLates 1 to cyclic carboxylic acid derivatives is described. The kinetic resolution of dioxolanones, azlactones and biaryl lactones by the Ti-TADDOLates affords